Adiponutrin/PNPLA3 Antibody [DyLight 350]
Novus Biologicals, part of Bio-Techne | Catalog # AF5208D
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry, Western Blot
Label
DyLight 350 (Excitation = 353 nm, Emission = 432 nm)
Antibody Source
Polyclonal Sheep IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
E. coli-derived recombinant human Adiponutrin/PNPLA3
Arg160-Arg349
Accession # Q9NST1
Arg160-Arg349
Accession # Q9NST1
Specificity
Detects human Adiponutrin/PNPLA3 in direct ELISAs and Western blots.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Applications for Adiponutrin/PNPLA3 Antibody [DyLight 350]
Application
Recommended Usage
Immunocytochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Adiponutrin/PNPLA3
Long Name
Patanin-like Phospholipase Domain-containing Protein 3
Alternate Names
ADPN, iPLA2-epsilon, PNPLA3
Gene Symbol
PNPLA3
Additional Adiponutrin/PNPLA3 Products
Product Documents for Adiponutrin/PNPLA3 Antibody [DyLight 350]
Product Specific Notices for Adiponutrin/PNPLA3 Antibody [DyLight 350]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...